Oncolytics Biotech
ONCY
76 hedge funds and large institutions have $3.76M invested in Oncolytics Biotech in 2026 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 7 closing their positions.
271% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 7
54% more capital inflows, than outflows
Capital inflows: $1.39M | Capital outflows: $901K
30% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 10
29% more funds holding
Funds holding: 59 → 76 (+17)
0.51% less ownership
Funds ownership: 3.84% → 3.33% (-0.51%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$187K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$172K |
| 3 |
Goldman Sachs
New York
|
+$158K |
| 4 |
XTX Topco
George Town,
Cayman Islands
|
+$140K |
| 5 |
HRT Financial
New York
|
+$95.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$606K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$106K |
| 3 |
Jane Street
New York
|
-$43.3K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$37.8K |
| 5 |
BCWM
Ball & Co Wealth Management
Franklin,
Tennessee
|
-$32K |
ONCY Hedge Fund Activity: Q2 2026 in Review
76 of the 8,354 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q2 2026, worth a combined $3.76M — up 13% from $3.34M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ONCY positions and 7 closed out — a net gain of 19 holders — while 13 added to existing stakes and 10 trimmed.
The largest buyer was International Assets Investment Management, opening a new position worth an estimated $187K. The largest seller was Renaissance Technologies, cutting an estimated $606K.
- 76 institutional investors held Oncolytics Biotech (ONCY) as of Q2 2026, up from 59 in Q1 2026.
- Funds reported $3.76M of Oncolytics Biotech stock for Q2 2026, up 13% quarter-over-quarter.
- 26 funds opened new Oncolytics Biotech positions in Q2 2026 and 7 closed out, a net change of +19 holders.
- The largest Oncolytics Biotech buyer in Q2 2026 was International Assets Investment Management, an estimated $187K added.
- The largest Oncolytics Biotech seller in Q2 2026 was Renaissance Technologies, an estimated $606K sold.
Based on aggregated 13F filings for Q2 2026.